Pregnancy decision-making in women with multiple sclerosis treated with natalizumabEmilio Portaccio, Eleonora Cocco, Maria Giovanna Marrosu et al.|Neurology|2018Cited by 123
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategiesPietro Iaffaldano, Giuseppe Lucisano, Francesca Caputo et al.|Therapeutic Advances in Neurological Disorders|2021Cited by 119
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational studyDamiano Baroncini, Angelo Ghezzi, Mauro Zaffaroni et al.|Multiple Sclerosis Journal|2018Cited by 62
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Diana Ferraro, Marta Simone et al.|JAMA Neurology|2021Cited by 62
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara Grazia Chisari, Francesco Corea, Giancarlo Comi et al.|Journal of Neurology|2021Cited by 15